Immunogenicity and safety of primary fractional-dose yellow fever vaccine in autoimmune rheumatic diseases

Imagem de Miniatura
Arquivos
art_TONACIO_Immunogenicity_and_safety_of_primary_fractionaldose_yellow_fever_2021.PDF (1.31 MB)
Citações na Scopus
4
Tipo de produção
article
Data de publicação
2021
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
PUBLIC LIBRARY SCIENCE
Autores
Citação
PLOS NEGLECTED TROPICAL DISEASES, v.15, n.11, article ID e0010002, 17p, 2021
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background Brazil faced a yellow fever(YF) outbreak in 2016-2018 and vaccination was considered for autoimmune rheumatic disease patients(ARD) with low immunosuppression due to YF high mortality. Objective This study aimed to evaluate, prospectively for the first time, the short-term immunogenicity of the fractional YF vaccine(YFV) immunization in ARD patients with low immunossupression. Methods and Results A total of 318 participants(159 ARD and 159 age- and sex-matched healthy controls) were vaccinated with the fractional-dose(one fifth) of 17DD-YFV. All subjects were evaluated at entry(D0), D5, D10, and D30 post-vaccination for clinical/laboratory and disease activity parameters for ARD patients. Post-vaccination seroconversion rate(83.7%vs.96.6%, p = 0.0006) and geometric mean titers(GMT) of neutralizing antibodies[1143.7 (95%CI 1012.3-1292.2) vs.731 (95%CI 593.6-900.2), p< 0.001] were significantly lower in ARD compared to controls. A lower positivity rate of viremia was also identified for ARD patients compared to controls at D5 (53%vs.70%, p = 0.005) and the levels persisted in D10 for patients and reduced for controls(51%vs.19%, p = 0.0001). The viremia was the only variable associated with seroconvertion. No serious adverse events were reported. ARD disease activity parameters remained stable at D30(p>0.05). Conclusion Fractional-dose 17DD-YF vaccine in ARD patients resulted in a high rate of seroconversion rate(> 80%) but lower than controls, with a longer but less intense viremia. This vaccine was immunogenic, safe and did not induce flares in ARD under low immunosuppression and may be indicated in YF outbreak situations and for patients who live or travel to endemic areas.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/45825
Referências
  1. Avelino-Silva VI, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005219
  2. Azevedo LS, 2012, TRANSPL INFECT DIS, V14, P237, DOI 10.1111/j.1399-3062.2011.00686.x
  3. Campi-Azevedo AC, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-391
  4. Casey RM, 2019, NEW ENGL J MED, V381, P444, DOI 10.1056/NEJMoa1710430
  5. Cook IF, 2008, VACCINE, V26, P3551, DOI 10.1016/j.vaccine.2008.04.054
  6. Croce E, 2017, VACCINE, V35, P1216, DOI 10.1016/j.vaccine.2017.01.048
  7. de Fontbrune FS, 2018, J INFECT DIS, V217, P494, DOI 10.1093/infdis/jix564
  8. de Verdiere NC, 2018, AIDS, V32, P2291, DOI 10.1097/QAD.0000000000001963
  9. Furer V, 2020, ANN RHEUM DIS, V79, P39, DOI 10.1136/annrheumdis-2019-215882
  10. Huber F, 2018, J TRAVEL MED, V25, DOI 10.1093/jtm/tax082
  11. Johansson MA, 2014, T ROY SOC TROP MED H, V108, P482, DOI 10.1093/trstmh/tru092
  12. Juan-Giner A, 2021, LANCET, V397, P119, DOI 10.1016/S0140-6736(20)32520-4
  13. Kohler S, 2012, EUR J IMMUNOL, V42, P2363, DOI 10.1002/eji.201142306
  14. Lindsey NP, 2008, VACCINE, V26, P6077, DOI 10.1016/j.vaccine.2008.09.009
  15. Mantel N, 2008, J VIROL METHODS, V151, P40, DOI 10.1016/j.jviromet.2008.03.026
  16. Martins RD, 2018, VACCINE, V36, P4112, DOI 10.1016/j.vaccine.2018.05.041
  17. Martins RD, 2015, HUM VACC IMMUNOTHER, V11, P2183, DOI 10.1080/21645515.2015.1022700
  18. Ministerio da Saude, 2018, MON PER SAZ FEBR AMA, V26, P1
  19. Monath TP, 2015, J CLIN VIROL, V64, P160, DOI 10.1016/j.jcv.2014.08.030
  20. Muniz LF, 2014, REV BRAS REUMATOL, V54, P349, DOI 10.1016/j.rbr.2014.04.002
  21. Muyanja E, 2014, J CLIN INVEST, V124, P3147, DOI 10.1172/JCI75429
  22. Oliveira ACV, 2015, ARTHRITIS RHEUMATOL, V67, P582, DOI 10.1002/art.38960
  23. OPS, 2018, YELLOW FEV BRAZ
  24. Organization WH, 2018, CAUSALITY ASSESSMENT, Vsecond
  25. Pileggi GS, 2019, ADV RHEUMATOL, V59, DOI 10.1186/s42358-019-0056-x
  26. Querec TD, 2009, NAT IMMUNOL, V10, P116, DOI 10.1038/ni.1688
  27. Roukens AH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027753
  28. Saad CGS, 2011, ANN RHEUM DIS, V70, P1068, DOI 10.1136/ard.2011.150250
  29. Silva ML, 2011, VACCINE, V29, P583, DOI 10.1016/j.vaccine.2010.08.046
  30. Simoes M, 2012, BIOLOGICALS, V40, P399, DOI 10.1016/j.biologicals.2012.09.005
  31. Sociedade Brasileira de Reumatologia (SBR) Sociedade Brasileira de Imunizac Brasileira de Infectologia (SBI) Sociedade Brasileira de Medicina Tropical(SBMT), 2018, SOC NOTA TECN CONJ V
  32. Valim V, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01382
  33. van Assen S, 2011, ANN RHEUM DIS, V70, P414, DOI 10.1136/ard.2010.137216
  34. Veit O, 2018, CLIN INFECT DIS, V66, P1099, DOI 10.1093/cid/cix960
  35. WHO, 2012, WORLD MALARIA REPORT 2012, P1
  36. World Hlth Org, 2017, VACCINE, V35, P5751, DOI 10.1016/j.vaccine.2017.06.087

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - FM/MPE
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/ICr
Carregar mais